Genmab A (GMAB) Raw Materials (2023 - 2025)

Genmab A has reported Raw Materials for 3 years, with the latest figure at $6.0 million in Q4 2025.

• For the quarter ending Q4 2025, Raw Materials rose 500.0% year-over-year to $6.0 million; the trailing twelve-month figure through Dec 2025 stood at $6.0 million (up 500.0% YoY), and the FY2025 full-year result was $6.0 million, up 500.0% from the prior year.
• Raw Materials for Q4 2025 stood at $6.0 million, up from $1.0 million in the prior quarter.
• The five-year high for Raw Materials was $6.0 million in Q4 2025, with the low at $1.0 million in Q4 2024.
• Historically, Raw Materials has averaged $3.0 million across 3 years, with a median of $2.0 million in 2023.
• Annual changes were most pronounced in 2024 — Raw Materials sank 50.0% — and 2025, when it soared 500.0%.
• Genmab A's Raw Materials stood at $2.0 million in 2023, then slumped by 50.0% to $1.0 million in 2024, then soared by 500.0% to $6.0 million in 2025.
• The last three Raw Materials figures came in at $6.0 million (Q4 2025), $1.0 million (Q4 2024), and $2.0 million (Q4 2023), per Business Quant data.